London-based Huma Therapeutics has closed a Series C funding round at $130 million. Led by Leaps by Bayer and Hitachi Ventures, Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures, and HAT Technology & Innovation Fund by HAT, also participated, as well as individual investors Nikesh Arora and Michael Diekmann.
As part of the round, an additional $70 million can be accessed at a later date, effectively bringing the raise to $200 million.
Huma reports that the funding will be used to scale their modular ‘hospitals at home’ platform in the UK, as well as support the largest decentralised clinical trials for the pharmaceutical and research industries in the US, Asia, and Middle East markets.
“Aligned with the vision of Leaps by Bayer, Huma’s expertise and technology will help drive a global paradigm shift towards prevention and care and may boost research efforts using data and digital technology,” comments Leaps by Bayer’s Juergen Eckhardt.
Founded in 2011 by Dan Vahdat and Rich Khatib, the Huma platform combines a proprietary predictive algorithm, biomarkers, and real-world data to effectively double clinical capacity, and reduce hospital readmission rates by one-third.
“We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago,” comments CEO Dan Vahdat. “Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide.’’